Imatinib mesylate in combination with other chemotherapeutic drugs: In vitro studies

Seminars in Hematology

Volumn 40, Issue 2 SUPPL. 2, 2003, Pages 83-91

  Tipping, Alex J ^a   Melo, Junia V ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 HYDROPEROXYCYCLOPHOSPHAMIDE; ADAPHOSTIN; AG 957; ALPHA INTERFERON; ARSENIC TRIOXIDE; BUSULFAN; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLAVOPIRIDOL; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; LONAFARNIB; MAFOSFAMIDE; METHOTREXATE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TREOSULFAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TYRPHOSTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; WORTMANNIN; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RECURRENCE; CELL LINE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; PREDICTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; DRUG EFFECT; DRUG INTERACTION; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG INTERACTIONS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 0038700985     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/shem.2003.50047     Document Type: Conference Paper

References (44)

1. An WG, Schulte TW, Neckers LM: The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 11:355-360, 2000
2. Blagosklonny MV: STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon'. Leukemia 16:570-572, 2002
3. Blagosklonny MV, Fojo T, Bhalla KN, et al: The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia 15:1537-1543, 2001
4. Boucher C: Rational approaches to resistance: Using saquinavir. AIDS 10:S15-S19, 1996 (suppl)
5. Chou TC, Motzer RJ, Tong Y, et al: Computerized quantitation of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design. J Natl Cancer Inst 86:1517-1524, 1994
6. Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001
7. Fang G, Kim CN, Perkins CL, et al: CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 96:2246-2253, 2000
8. Gorre ME, Mohammed M, Ellwood K, et al: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880, 2001
9. Hoover RR, Mahon FX, Melo JV, et al: Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 100:1068-1071, 2002
10. Kano Y, Akutsu M, Tsunoda S, et al: In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97:1999-2007, 2001
11. Keeshan K, Mills KI, Cotter TG, et al: Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype. Leukemia 15:1823-1833, 2001.
12. Klejman A, Rushen L, Morrione A, et al: Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene 21:5868-5876, 2002
13. La Rosee P, Johnson K, O'Dwyer ME, et al: In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol 30:729-737, 2002
14. le Coutre P, Tassi E, Varella-Garcia M, et al: Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95:1758-1766, 2000
15. Luzzatto L, Melo JV: Acquired resistance to imatinib mesylate: Selection for pre-existing mutant cells. Blood 100:1105, 2002
16. Mahon FX, Deininger MW, Schultheis B, et al: Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance. Blood 96:1070-1079, 2000
17. Marley SB, Davidson RJ, Goldman JM, et al: Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia. Br J Haematol 116:162-165, 2002
18. Marley SB, Deininger MW, Davidson RJ, et al: The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. Exp Hematol 28:551-557, 2000
19. Mow BM, Chandra J, Svingen PA, et al: Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 99:664-671, 2002
20. Moyle G: Resistance and cross-resistance to abacavir. HIV Med 2:154-162, 2001
21. Murgo AJ: Clinical trials of arsenic trioxide in hematologic and solid tumors: Overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist 6:22-28, 2001 (suppl)
22. Nagar B, Bornmann WG, Pellicena P, et al: Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62:4236-4243, 2002
23. Newlands ES, Rustin GJ, Brampton MH: Phase I trial of elactocin. Br J Cancer 74:648-649, 1996
24. Nimmanapalli R, O'Bryan E, Bhalla K: Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr- Abl-positive human leukemic blasts. Cancer Res 61:1799-1804, 2001
25. Nimmanapalli R, Porosnicu M, Nguyen D, et al: Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clin Cancer Res 7:350-357, 2001
26. 3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells. Leukemia 15:772-778, 2001
27. Ridky T, Leis J: Development of drug resistance to HIV-1 protease inhibitors. J Biol Chem 270:29621-29623, 1995
28. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al: Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100:1014-1018, 2002
29. Scappini B, Onida F, Kantarjian HM, et al: In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer 94:2653-2662, 2002
30. Senderowicz AM, Headlee D, Stinson SF, et al: Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16:2986-2999, 1998
31. Shah N, Nicoll J, Nagar B, et al: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125, 2002
32. Skorski T, Kanakaraj P, Nieborowska SM, et al: Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86:726-736, 1995
33. Steel GG, Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity. Int J Radiat Oncol Biol Phys 5:85-91, 1979
34. Sun X, Layton JE, Elefanty A, et al: Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL-expressing cells, demonstrating synergy between AG490 and STI571. Blood 97:2008-2015, 2001
35. Thiesing JT, Ohno-Jones S, Kolibaba KS, et al: Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 96:3195-3199, 2000
36. Tipping AJ, Mahon FX, Lagarde V, et al: Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells. Blood 98:3864-3867, 2001
37. Tipping AJ, Mahon FX, Zafirides G, et al: Drug responses of imatinib mesylate-resistant cells: Synergism of imatinib with other chemotherapeutic drugs. Leukemia 16:2349-2357, 2002
38. Topaly J, Fruehauf S, Ho AD, et al: Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: Implications for pretransplant conditioning. Br J Cancer 86:1487-1493, 2002
39. Topaly J, Zeller WJ, Fruehauf S: Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 15:342-347, 2001
40. Vigneri P, Wang JY: Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 7:228-234, 2001
41. Weisberg E, Griffin JD: Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 95:3498-3505, 2000
42. Wisniewski D, Lambek CL, Liu C, et al: Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res 62:4244-4255, 2002
43. Yu C, Krystal G, Dent P, et al: Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clin Cancer Res 8:2976-2984, 2002
44. Yu C, Krystal G, Varticovksi L, et al: Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res 62:188-199, 2002